(S)-5-(7-(2-((3-chloro-6-(2,4-dimethylpiperazin-1-yl)-2-fluoropyridin-4-yl)amino)-2-oxoethyl)-2-methoxy-3-methyl-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)-3,4-difluoro-2-hydroxybenzamide

ID: ALA5284699

Chembl Id: CHEMBL5284699

Max Phase: Preclinical

Molecular Formula: C28H28ClF3N8O5

Molecular Weight: 649.03

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1nc2c(c(-c3cc(C(N)=O)c(O)c(F)c3F)cn2CC(=O)Nc2cc(N3CCN(C)C[C@@H]3C)nc(F)c2Cl)c(=O)n1C

Standard InChI:  InChI=1S/C28H28ClF3N8O5/c1-12-9-37(2)5-6-40(12)17-8-16(20(29)24(32)35-17)34-18(41)11-39-10-15(19-26(39)36-28(45-4)38(3)27(19)44)13-7-14(25(33)43)23(42)22(31)21(13)30/h7-8,10,12,42H,5-6,9,11H2,1-4H3,(H2,33,43)(H,34,35,41)/t12-/m0/s1

Standard InChI Key:  YAULVJSIQRRWRW-LBPRGKRZSA-N

Alternative Forms

  1. Parent:

    ALA5284699

    ---

Associated Targets(Human)

BCL6 Tchem B-cell lymphoma 6 protein (838 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KARPAS-422 (454 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 649.03Molecular Weight (Monoisotopic): 648.1823AlogP: 2.46#Rotatable Bonds: 7
Polar Surface Area: 160.84Molecular Species: ACIDHBA: 11HBD: 3
#RO5 Violations: 2HBA (Lipinski): 13HBD (Lipinski): 4#RO5 Violations (Lipinski): 2
CX Acidic pKa: 6.30CX Basic pKa: 7.61CX LogP: 2.80CX LogD: 2.75
Aromatic Rings: 4Heavy Atoms: 45QED Weighted: 0.26Np Likeness Score: -1.03

References

1. Mamai A, Chau AM, Wilson BJ, Watson ID, Joseph BB, Subramanian PR, Morshed MM, Morin JA, Prakesch MA, Lu T, Connolly P, Kuntz DA, Pomroy NC, Poda G, Nguyen K, Marcellus R, Strathdee G, Theriault B, Subramaniam R, Mohammed M, Abibi A, Chan M, Winston J, Kiyota T, Undzys E, Aman A, Austin N, Du Jardin M, Packman K, Phillippar U, Attar R, Edwards J, O'Meara J, Uehling DE, Al-Awar R, Privé GG, Isaac MB..  (2023)  Discovery of OICR12694: A Novel, Potent, Selective, and Orally Bioavailable BCL6 BTB Inhibitor.,  14  (2.0): [PMID:36793435] [10.1021/acsmedchemlett.2c00502]

Source